Cargando…
Antiresorptive effect of a cathepsin K inhibitor ONO-5334 and its relationship to BMD increase in a phase II trial for postmenopausal osteoporosis
BACKGROUND: ONO-5334 is a cathepsin K inhibitor that induced bone mineral density (BMD) gain in a phase II study in postmenopausal osteoporosis patients. Even though the antiresorptive effect could only be monitored in the morning during the study, simulation can allow the antiresorptive effect to b...
Autores principales: | Tanaka, Makoto, Hashimoto, Yoshitaka, Hasegawa, Chihiro, Deacon, Steve, Eastell, Richard |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5477094/ https://www.ncbi.nlm.nih.gov/pubmed/28629344 http://dx.doi.org/10.1186/s12891-017-1625-y |
Ejemplares similares
-
Effects of the Cathepsin K Inhibitor ONO-5334 and Concomitant Use of ONO-5334 with Methotrexate on Collagen-Induced Arthritis in Cynomolgus Monkeys
por: Yamada, Hiroyuki, et al.
Publicado: (2019) -
Morning vs evening dosing of the cathepsin K inhibitor ONO-5334: effects on bone resorption in postmenopausal women in a randomized, phase 1 trial
por: Eastell, R., et al.
Publicado: (2015) -
New Antiresorptive Therapies for Postmenopausal Osteoporosis
por: Choi, Hee-Jeong
Publicado: (2015) -
Antiresorptive Versus Anabolic Therapy in Managing Osteoporosis in People with Type 1 and Type 2 Diabetes
por: Vilaca, Tatiane, et al.
Publicado: (2023) -
Antiresorptive Drugs Beyond Bisphosphonates and Selective Oestrogen Receptor Modulators for the Management of Postmenopausal Osteoporosis
por: Reginster, J. Y., et al.
Publicado: (2014)